Navigation Links
Clinical Genomics Continues Collaborative Research With CSIRO

SYDNEY, Oct. 7 /PRNewswire/ -- Sydney-based Clinical Genomics Pty Ltd and CSIRO have entered into a new phase in their collaboration to develop improved diagnostics for cancers of the colon and rectum (bowel cancer).

In an earlier research program, Clinical Genomics and researchers from CSIRO's Preventative Health Flagship used advanced genomics and mathematics to identify a number of biomarker genes capable of differentiating between bowel cancer tissue, even at its very earliest stages, and normal bowel tissue. Clinical Genomics and CSIRO have filed jointly-owned patents based on these discoveries.

While this initial research is exciting, the next challenge will be to identify which of these biomarkers can be found in clinical samples, such as blood or stool, with the accuracy to improve diagnosis of bowel cancer. The new collaboration between Clinical Genomics and CSIRO is aimed at addressing this challenge with a particular emphasis on biomarkers for the early treatable stages of disease.

CSIRO has developed a suite of molecular technologies that improve detection of DNA methylation - a chemical change to the structure of DNA associated with some candidate biomarker genes.

CSIRO and Clinical Genomics will now use these proprietary technologies to research and develop a clinical test aimed at testing patient blood and stool for the early detection of bowel cancer. If this research is successful, these assays will be commercially developed and delivered by Clinical Genomics.

Clinical Genomics' CEO, Lawrence LaPointe, says the decision to extend the collaborative relationship between the company and CSIRO should reap rewards.

"We believe that CSIRO offers both innovative technologies and world-class scientists in the field of DNA diagnostics for cancer," Mr LaPointe says. "Both of these resources will be a key factor in achieving success in this project."

The leader of CSIRO's Colorectal Cancer and Gut Health Theme, Dr. Trevor Lockett, says the agreement is an important strategic initiative.

"It provides a strong pathway to achieving both Clinical Genomics' and CSIRO's shared goal of improving the diagnosis and prognosis of bowel cancer and thereby reducing the impact of this debilitating disease on patients in Australia and globally."

         Further Information:
         Dr. Lindsay Collinson,
         Clinical Genomics Pty Ltd
         Ph: +61 2 9888 9065 ext. 206
         Mb: +61 400 995 617

SOURCE Clinical Genomics Pty Ltd

SOURCE Clinical Genomics Pty Ltd
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. HerbalScience Releases Results of Pilot Clinical Study on Efficacy of Its Proprietary Elderberry Extract in Addressing Flu-Like Symptoms
2. Boston Scientific Announces Exclusive Sponsorship and First Enrollments of MADIT-RIT Clinical Trial
3. Medicago begins human clinical testing with its avian flu pandemic vaccine
4. MacuSight(R) Provides Clinical Development Update for Perceiva(TM)
5. Resverlogix RVX-208 Second Clinical Trial Demonstrates Success on Key Reverse Cholesterol Transport Markers
6. ClearTrial Launches Industry-first Software Platform for Integrating Clinical Trial Operations from Plan to Cash™, Driving Operational Efficiencies and Accelerating Clinical Development
7. Final 12 Month Clinical Data from 5,000 Patients in Worldwide e-HEALING Clinical Study Show Good Safety and Efficacy with Real World Use of OrbusNeichs Genous(TM) Bio-engineered R stent(TM)
8. DIA/FDA/PhRMA Conference To Expand The Role Of Modeling And Simulation In Clinical Drug Development
9. Micromet Appoints Former Roche Oncology Clinical Leader Jan Fagerberg as Chief Medical Officer
10. PROLOR Biotech Announces Initiation of Phase I Clinical Trial for its Long-Acting Growth Hormone
11. Clinical Trials Move to Emerging Regions, Heighten Need for Local Risk Consulting: Aon Global Risk Map
Post Your Comments:
(Date:6/23/2016)... Md. , June 23, 2016 A person ... from the crime scene to track the criminal down. ... the U.S. Food and Drug Administration (FDA) uses DNA evidence ... Sound far-fetched? It,s not. The FDA ... sequencing to support investigations of foodborne illnesses. Put as simply ...
(Date:6/23/2016)... -- The Prostate Cancer Foundation (PCF) is pleased to announce 24 new ... prostate cancer. Members of the Class of 2016 were selected from a pool ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... 23, 2016 , ... Supplyframe, the Industry Network for electronics ... Lab . Located in Pasadena, Calif., the Design Lab’s mission is to bring ... designed, built and brought to market. , The Design Lab is Supplyframe’s physical ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
Breaking Biology Technology:
(Date:4/15/2016)... , April 15, 2016 ... "Global Gait Biometrics Market 2016-2020,"  report to their ... ) , ,The global gait biometrics market ... 13.98% during the period 2016-2020. Gait ... which can be used to compute factors that ...
(Date:4/13/2016)... CHICAGO , April 13, 2016  IMPOWER physicians ... are setting a new clinical standard in telehealth ... By leveraging the higi platform, IMPOWER patients can ... weight, pulse and body mass index, and, when they ... quick and convenient visit to a local retail location ...
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
Breaking Biology News(10 mins):